Eosinophilic Esophagitis Symptom Scores Are High in Children Without Eosinophilic Disease.
Journal
Journal of pediatric gastroenterology and nutrition
ISSN: 1536-4801
Titre abrégé: J Pediatr Gastroenterol Nutr
Pays: United States
ID NLM: 8211545
Informations de publication
Date de publication:
01 03 2022
01 03 2022
Historique:
pubmed:
13
10
2021
medline:
3
5
2022
entrez:
12
10
2021
Statut:
ppublish
Résumé
The Pediatric Eosinophilic Esophagitis (EoE) Symptom Score version 2 (PEESSv2.0) is an EoE-specific validated metric for disease monitoring, but its use has not been explored outside of EoE. Our aim was to determine if PEESSv2.0 scores differentiate between children with EoE and non-EoE esophageal dysfunction undergoing initial esophagogastroduodenoscopy (EGD). A prospective cohort study of pediatric subjects was conducted. Children ages 1-18 undergoing initial EGD for esophageal dysfunction were enrolled. Demographics, clinical history, and child self-report and parent-proxy report PEESSv2.0 symptom scores were collected at the time of EGD. Esophageal biopsies were reviewed, and EoE was defined as >15 eosinophils/high powered field (hpf) seen in any level of the esophagus. Non-EoE was defined as <15 eosinophils/hpf. Seventy-one children were included in the study from 2015 to 2018 [59% (42/71) males; mean age 9.2 years; range 1-17 years]. Fifty-eight percent (41/71) met criteria for EoE, and 42% (30/71) were labeled non-EoE. Non-EoE children and their parents had higher/worse median PEESSv2.0 total scores than those with EoE [47.0 vs 28.0 (P = 0.001) and 40.5 vs 26.5 (P = 0.012), respectively]. Non-EoE children reported higher median GERD [9.0 vs 4.0 (P = 0.003)], nausea/vomiting [9.0 vs 4.0 (P = 0.003)], and pain [11.0 vs 6.0 (P = 0.001)] subdomain scores compared to those with EoE. PEESSv2.0 dysphagia subdomain scores (child and parent-proxy) did not differ between EoE and non-EoE groups [22.0 vs 15.0 (P = 0.184) and 18.5 vs 17.4 (P = 0.330), respectively]. Total PEESSv2.0 scores were worse in non-EoE group compared to EoE group. Although PEESSv2.0 is validated for use in monitoring EoE therapy, it does not distinguish children with EoE from non-EoE esophageal dysfunction at the time of diagnostic EGD.
Identifiants
pubmed: 34636795
doi: 10.1097/MPG.0000000000003324
pii: 00005176-202203000-00016
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
396-401Informations de copyright
Copyright © 2021 by European Society for Pediatric Gastroenterology, Hepatology, and Nutrition and North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition.
Déclaration de conflit d'intérêts
Dr. Gupta is a consultant for Adare, Allakos, Celgene, Gossamer Bio, QOL, UpToDate, Medscape and Viaskin. He receives research support from Shire and an NIH U54 grant to the Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR), which do not affect this work. At the time of submitting revisions for this manuscript, Dr. Hon is a Clinical Research Physician for Eli Lilly and Company, and this position does not affect this work. She was solely associated with Indiana University School of Medicine/Riley Hospital for Children at the time of her contribution to this study. The other authors report no conflicts of interest.
Références
Dellon ES, Gonsalves N, Hirano I, et al. ACG clinical guideline: Evidenced based approach to the diagnosis and management of esophageal eosinophilia and eosinophilic esophagitis (EoE). Am J Gastroenterol 2013; 108:679–692. quiz 93.
Dellon ES, Jensen ET, Martin CF, et al. Prevalence of eosinophilic esophagitis in the United States. Clin Gastroenterol Hepatol 2014; 12:589.e1–596.e1.
Mansoor E, Cooper GS. The 2010−2015 prevalence of eosinophilic esophagitis in the USA: a population-based study. Dig Dis Sci 2016; 61:2928–2934.
Robson J, O’Gorman M, McClain A, et al. Incidence and prevalence of pediatric eosinophilic esophagitis in Utah based on a 5-year population-based study. Clin Gastroenterol Hepatol 2019; 17:107.e1–114.e1.
Dellon ES, Liacouras CA, Molina-Infante J, et al. Updated international consensus diagnostic criteria for eosinophilic esophagitis: proceedings of the AGREE conference. Gastroenterology 2018; 155:1022.e10–1033.e10.
Godwin B, Wilkins B. Muir AB EoE disease monitoring: where we are and where we are going. Ann Allergy Asthma Immunol 2020; 124:240–247.
Furuta GT, Kagalwalla AF, Lee JJ, et al. The oesophageal string test: a novel, minimally invasive method measures mucosal inflammation in eosinophilic oesophagitis. Gut 2013; 62:1395–1405.
Katzka DA, Geno DM, Ravi A, et al. Accuracy, safety, and tolerability of tissue collection by cytosponge vs endoscopy for evaluation of eosinophilic esophagitis. Clin Gastroenterol Hepatol 2015; 13:77.e2–83.e2.
Wechsler JB, Ackerman SJ, Chehade M, et al. Noninvasive biomarkers identify eosinophilic esophagitis: a prospective longitudinal study in children. Allergy 2021; doi: 10.1111/all.14874. [Epub ahead of print].
doi: 10.1111/all.14874.
Liacouras CA, Furuta GT, Hirano I, et al. Eosinophilic esophagitis: updated consensus recommendations for children and adults. J Allergy Clin Immunol 2011; 128:3.e6–20.e6. quiz 21−2.
Hines BT, Rank MA, Wright BL, et al. Minimally invasive biomarker studies in eosinophilic esophagitis: a systematic review. Ann Allergy Asthma Immunol 2018; 121:218–228.
Hudgens S, Evans C, Phillips E, et al. Psychometric validation of the Dysphagia Symptom Questionnaire in patients with eosinophilic esophagitis treated with budesonide oral suspension. J Patient Rep Outcomes 2017; 1:3.
Franciosi JP, Hommel KA, DeBrosse CW, et al. Development of a validated patient-reported symptom metric for pediatric eosinophilic esophagitis: qualitative methods. BMC Gastroenterol 2011; 11:126.
Franciosi JP, Hommel KA, Greenberg AB, et al. Development of the Pediatric Quality of Life Inventory Eosinophilic Esophagitis module items: qualitative methods. BMC Gastroenterol 2012; 12:135.
Myer CMt, Howell RJ, Cohen AP, et al. A systematic review of patient- or proxy-reported validated instruments assessing pediatric dysphagia. Otolaryngol Head Neck Surg 2016; 154:817–823.
Pentiuk S, Putnam PE, Collins MH, et al. Dissociation between symptoms and histological severity in pediatric eosinophilic esophagitis. J Pediatr Gastroenterol Nutr 2009; 48:152–160.
Aceves SS, King E, Collins MH, et al. Alignment of parent- and child-reported outcomes and histology in eosinophilic esophagitis across multiple CEGIR sites. J Allergy Clin Immunol 2018; 142:130.e1–138.e1.
Sperry SL, Woosley JT, Shaheen NJ, et al. Influence of race and gender on the presentation of eosinophilic esophagitis. Am J Gastroenterol 2012; 107:215–221.
Dellon ES, Gibbs WB, Fritchie KJ, et al. Clinical, endoscopic, and histologic findings distinguish eosinophilic esophagitis from gastroesophageal reflux disease. Clin Gastroenterol Hepatol 2009; 7:1305–1313. quiz 261.
Assa’ad AH, Putnam PE, Collins MH, et al. Pediatric patients with eosinophilic esophagitis: an 8-year follow-up. J Allergy Clin Immunol 2007; 119:731–738.
Lipowska AM, Kavitt RT. Demographic features of eosinophilic esophagitis. Gastrointest Endosc Clin N Am 2018; 28:27–33.
Miehlke S. Clinical features of eosinophilic esophagitis. Dig Dis 2014; 32:61–67.
Riehl ME, Keefer L. Hypnotherapy for esophageal disorders. Am J Clin Hypn 2015; 58:22–33.
Taft TH, Triggs JR, Carlson DA, et al. Validation of the oesophageal hypervigilance and anxiety scale for chronic oesophageal disease. Aliment Pharmacol Ther 2018; 47:1270–1277.
Keefer LCJ, Dowjotas K, Kahrilas IJ, et al. Symptoms reporting among PPI non responders may be driven by esophageal hyervigilance and not reflux type. Gastroenterology 2015; 148:S-147.
Kahrilas PJ, Keefer L, Pandolfino JE. Patients with refractory reflux symptoms: what do they have and how should they be managed? Neurogastroenterol Motil 2015; 27:1195–1201.
Carlson DA, Gyawali CP, Roman S, et al. Esophageal hypervigilance and visceral anxiety are contributors to symptom severity among patients evaluated with high-resolution esophageal manometry. Am J Gastroenterol 2020; 115:367–375.
Nelson M, Zhang X, Pan Z, et al. Mast cell effects on esophageal smooth muscle and their potential role in eosinophilic esophagitis and achalasia. Am J Physiol Gastrointest Liver Physiol 2021; 320:G319–G327.
Lucendo AJ, Bellon T. Lucendo B The role of mast cells in eosinophilic esophagitis. Pediatr Allergy Immunol 2009; 20:512–518.
Straumann A, Bauer M, Fischer B, et al. Idiopathic eosinophilic esophagitis is associated with a T(H)2-type allergic inflammatory response. J Allergy Clin Immunol 2001; 108:954–961.
Gupta SK, Fitzgerald JF, Kondratyuk T, et al. Cytokine expression in normal and inflamed esophageal mucosa: a study into the pathogenesis of allergic eosinophilic esophagitis. J Pediatr Gastroenterol Nutr 2006; 42:22–26.
Reed CC, Genta RM, Youngblood BA, et al. Mast cell and eosinophil counts in gastric and duodenal biopsies from patients with and without eosinophilic gastroenteritis. Clin Gastroenterol Hepatol 2021; 19:2102–2111.
Bolton SM, Kagalwalla AF, Arva NC, et al. Mast cell infiltration is associated with persistent symptoms and endoscopic abnormalities despite resolution of eosinophilia in pediatric eosinophilic esophagitis. Am J Gastroenterol 2020; 115:224–233.
Dellon ES, Aderoju A, Woosley JT, et al. Variability in diagnostic criteria for eosinophilic esophagitis: a systematic review. Am J Gastroenterol 2007; 102:2300–2313.